Imvaria

Tagline Brand's website · 2026-10-04

Pioneers 'inferetics' by generating novel physiologic signatures from clinical testing and imaging data using AI; offers the first FDA-authorized tools in ILD and IPF (ScreenDx, Fibresolve); led by physician-engineers from Google and Stanford; provides a simple-to-start, no-integration solution.

Description Brand's website · 2026-10-04

IMVARIA pioneers AI inference across clinical testing and imaging to generate novel physiologic signatures, creating "inferetics" – a new category of clinical intelligence. They develop FDA-authorized Software-as-Medical-Device (SaMD) tools, initially focused on lung diseases like ILD and IPF, for clinicians, health systems, and biopharma partners.

Core capabilities Brand's website · 2026-10-04

• ScreenDx (AI for ILD identification)
• Fibresolve (AI for IPF diagnosis)
• The AI Lab (cloud-based data analysis platform)
• Bronchosolve (AI for non-invasive lung cancer diagnosis).

Pricing Brand's website · 2026-10-04

Service-based model, where clinicians refer cases to IMVARIA's AI Lab and receive reports with results; no integration or software required from the client.

Target industry Brand's website · 2026-10-04

Pulmonologists, qualified clinicians in lung disease care, health systems, clinical trialists, and biopharma partners.